HKHajo Kries

Hajo Kries

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hajo Kries has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksa Stanišić

    Biosynthetic Design of Natural Products, Leibniz Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute (HKI), Beutenbergstraße 11a, 07745 Jena, Germany

    10 shared publications
  • Philipp Stephan

    Junior Research Group Biosynthetic Design of Natural Products Leibniz Institute for Natural Product Research and Infection Biology (HKI) Beutenbergstr. 11a 07745 Jena Germany

    10 shared publications
  • Sarah Ellen O'COnnor

    Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology

    9 shared publications
  • Christian Hertweck

    Department of Biomolecular Chemistry, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI), Jena, Germany

    6 shared publications
  • Donald Hilvert

    Laboratory of Organic Chemistry, ETH Zurich, Zurich, Switzerland

    6 shared publications
  • Donald Hilvert

    Department of Chemistry and Applied Biosciences, Laboratory of Organic Chemistry, Swiss Federal Institute of Technology Zurich (ETH Zurich), 8093, Zurich, Switzerland

    4 shared publications

Latest Publications

  • Open Access

    Adenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic

    by Maximilian Müll, Pia Lanvers, Giulia Ravagnan, Kilian Klaus, Olena Nosovska, Ivan Vilotijevic, Jochen Schmid, Hajo Kries

    Polymyxins are potent nonribosomal peptide antibiotics, yet their clinical use is limited by a narrow therapeutic window and nephro‐/neurotoxicity. Conventional efforts to improve these agents rely on the incorporation of nonnatural building blocks that cannot be accessed biosynthetically and therefore must be introduced by total synthesis. Here we report a biosynthetic route to a next‐generation polymyxin that circumvents this limitation. By engineering the substrate‐binding pocket of a nonribosomal adenylation (A‐)domain, we created a mutationally expanded pocket that selectively activates the fatty amino acid l ‐2‐aminodecanoic acid ( l ‐Ada). Incorporation of this engineered A‐domain into the native polymyxin biosynthesis enabled production of Ada‐polymyxin with high potential for lowered toxicity directly in Paenibacillus polymyxa fermentation. This work demonstrates that rational redesign of nonribosomal A‐domains can redirect natural product biosynthesis toward chemically diverse, therapeutically superior antibiotics, opening new avenues for combating drug‐resistant bacteria.

  • Open Access

    Adenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic

    by Maximilian Müll, Pia Lanvers, Giulia Ravagnan, Kilian Klaus, Olena Nosovska, Ivan Vilotijevic, Jochen Schmid, Hajo Kries

    Polymyxins are potent nonribosomal peptide antibiotics, yet their clinical use is limited by a narrow therapeutic window and nephro‐/neurotoxicity. Conventional efforts to improve these agents rely on the incorporation of nonnatural building blocks that cannot be accessed biosynthetically and therefore must be introduced by total synthesis. Here we report a biosynthetic route to a next‐generation polymyxin that circumvents this limitation. By engineering the substrate‐binding pocket of a nonribosomal adenylation (A‐)domain, we created a mutationally expanded pocket that selectively activates the fatty amino acid l ‐2‐aminodecanoic acid ( l ‐Ada). Incorporation of this engineered A‐domain into the native polymyxin biosynthesis enabled production of Ada‐polymyxin with high potential for lowered toxicity directly in Paenibacillus polymyxa fermentation. This work demonstrates that rational redesign of nonribosomal A‐domains can redirect natural product biosynthesis toward chemically diverse, therapeutically superior antibiotics, opening new avenues for combating drug‐resistant bacteria.

  • Open Access

    Mapping the nonribosomal specificity code through promiscuity-guided A-domain engineering

    by Aleksa Stanišić, Carl-Magnus Svensson, Maximilian Müll, Freddy A. Bernal, Hannah Zeihe, Ulrich Ettelt, Hajo Kries

    From specialist to generalist and back: probing active-site mutations defines a roadmap for redesigning substrate specificity of adenylation domains from nonribsomal peptide synthesis.


  • Open Access

    Controlling Substrate- and Stereospecificity of Condensation Domains in Nonribosomal Peptide Synthetases

    by Huiyun Peng, Julian Schmiederer, Xiuqiang Chen, Gianni Panagiotou, Hajo Kries

    Nonribosomal peptide synthetases (NRPSs) are sophisticated molecular machines that biosynthesize peptide drugs. In attempts to generate new bioactive compounds, some parts of NRPSs have been successfully manipulated, but especially the influence of condensation (C-)domains on substrate specificity remains enigmatic and poorly controlled. To understand the influence of C-domains on substrate preference, we extensively evaluated the peptide formation of C-domain mutants in a bimodular NRPS system. Thus, we identified three key mutations that govern the preference for stereoconfiguration and side-chain identity. These mutations show similar effects in three different C-domains (GrsB1, TycB1, and SrfAC) when di- or pentapeptides are synthesized in vitro or in vivo. Strikingly, mutation E386L allows the stereopreference to be switched from d- to l-configured donor substrates. Our findings provide valuable insights into how cryptic specificity filters in C-domains can be re-engineered to clear roadblocks for NRPS engineering and enable the production of novel bioactive compounds.


  • Analysis of the Valgamicin Biosynthetic Pathway Reveals a General Mechanism for Cyclopropanol Formation across Diverse Natural Product Scaffolds

    by Rory F. Little, Felix Trottmann, Hideki Hashizume, Miriam Preissler, Sandra Unger, Ryuichi Sawa, Hajo Kries, Sacha Pidot, Masayuki Igarashi, Christian Hertweck

    Cyclopropanol rings are highly reactive and may function as molecular "warheads" that affect natural product bioactivity. Yet, knowledge on their biosynthesis is limited. Using gene cluster analyses, isotope labeling, and in vitro enzyme assays, we shed first light on the biosynthesis of the cyclopropanol-substituted amino acid cleonine, a residue in the antimicrobial depsipeptide valgamicin C and the cytotoxic glycopeptide cleomycin A2. We decipher the biosynthetic origin of valgamicin C and show that the cleonine cyclopropanol ring is derived from dimethylsulfoniopropionate (DMSP). Furthermore, we demonstrate that part of the biosynthesis is analogous to the formation of malleicyprol polyketides in pathogenic bacteria. By genome mining and metabolic profiling, we identify the potential to produce cyclopropanol rings in other bacterial species. Our results reveal a general mechanism for cyclopropyl alcohol biosynthesis across diverse natural products that may be harnessed for bioengineering and drug discovery.


  • Open Access

    Novel Biocatalysts from Specialized Metabolism

    by Hajo Kries, Felix Trottmann, Christian Hertweck

    Enzymes are increasingly recognized as valuable (bio)catalysts that complement existing synthetic methods. However, the range of biotransformations used in the laboratory is limited. Here we give an overview on the biosynthesis‐inspired discovery of novel biocatalysts that address various synthetic challenges. Prominent examples from this dynamic field highlight remarkable enzymes for protecting‐group‐free amide formation and modification, control of pericyclic reactions, stereoselective hetero‐ and polycyclizations, atroposelective aryl couplings, site‐selective C−H activations, introduction of ring strain, and N−N bond formation. We also explore unusual functions of cytochrome P450 monooxygenases, radical SAM‐dependent enzymes, flavoproteins, and enzymes recruited from primary metabolism, which offer opportunities for synthetic biology, enzyme engineering, directed evolution, and catalyst design.


  • Open Access

    Novel Biocatalysts from Specialized Metabolism

    by Hajo Kries, Felix Trottmann, Christian Hertweck

    Enzymes are increasingly recognized as valuable (bio)catalysts that complement existing synthetic methods. However, the range of biotransformations used in the laboratory is limited. Here we give an overview on the biosynthesis‐inspired discovery of novel biocatalysts that address various synthetic challenges. Prominent examples from this dynamic field highlight remarkable enzymes for protecting‐group‐free amide formation and modification, control of pericyclic reactions, stereoselective hetero‐ and polycyclizations, atroposelective aryl couplings, site‐selective C−H activations, introduction of ring strain, and N−N bond formation. We also explore unusual functions of cytochrome P450 monooxygenases, radical SAM‐dependent enzymes, flavoproteins, and enzymes recruited from primary metabolism, which offer opportunities for synthetic biology, enzyme engineering, directed evolution, and catalyst design.


  • Open Access

    Analysing Megasynthetase Mutants at High Throughput Using Droplet Microfluidics**

    by Farzaneh Pourmasoumi, Sundar Hengoju, Katharina Beck, Philipp Stephan, Lukas Klopfleisch, Maria Hoernke, Miriam A. Rosenbaum, Hajo Kries

    Nonribosomal peptide synthetases (NRPSs) are giant enzymatic assembly lines that deliver many pharmaceutically valuable natural products, including antibiotics. As the search for new antibiotics motivates attempts to redesign nonribosomal metabolic pathways, more robust and rapid sorting and screening platforms are needed. Here, we establish a microfluidic platform that reliably detects production of the model nonribosomal peptide gramicidin S. The detection is based on calcein‐filled sensor liposomes yielding increased fluorescence upon permeabilization. From a library of NRPS mutants, the sorting platform enriches the gramicidin S producer 14.5‐fold, decreases internal stop codons 250‐fold, and generates enrichment factors correlating with enzyme activity. Screening for NRPS activity with a reliable non‐binary sensor will enable more sophisticated structure‐activity studies and new engineering applications in the future.


  • Open Access

    Biosynthetic incorporation of fluorinated amino acids into the nonribosomal peptide gramicidin S

    by Maximilian Müll, Farzaneh Pourmasoumi, Leon Wehrhan, Olena Nosovska, Philipp Stephan, Hannah Zeihe, Ivan Vilotijevic, Bettina G. Keller, Hajo Kries

    Fluorine is a key element in medicinal chemistry, as it can significantly enhance the pharmacological properties of drugs. In this study, we aimed to biosynthetically produce fluorinated analogues of the antimicrobial cyclic decapeptide gramicidin S (GS). However, our results show that the A-domain of the NRPS module GrsA rejects 4-fluorinated analogues of its native substrate Phe due to an interrupted T-shaped aromatic interaction in the binding pocket. We demonstrate that GrsA mutant W239S improves the incorporation of 4-fluorinated Phe into GS both in vitro and in vivo. Our findings provide new insights into the behavior of NRPSs towards fluorinated amino acids and strategies for the engineered biosynthesis of fluorinated peptides.


  • Open Access

    Gerichtete Evolution von Piperazinsäureeinbau durch eine Nichtribosomale Peptidsynthetase**

    by Philipp Stephan, Chloe Langley, Daniela Winkler, Jérôme Basquin, Lorenzo Caputi, Sarah E. O'COnnor, Hajo Kries

    Das Engineering biosynthetischer Enzyme wird zunehmend eingesetzt, um strukturelle Analoga von Antibiotika zu synthetisieren. Von besonderem Interesse sind nichtribosomale Peptidsynthetasen (NRPS), die für die Produktion wichtiger antimikrobieller Peptide verantwortlich sind. Hier beschreiben wir, wie durch gerichtete Evolution einer Adenylierungsdomäne eines Pro‐spezifischen NRPS‐Moduls dessen Substratspezifität vollständig auf die Nicht‐Standard‐Aminosäure Piperazinsäure (Piz) geändert wurde, welche eine labile N−N‐Bindung enthält. Dieser Erfolg wurde durch UPLC‐MS/MS‐basiertes Screening kleiner, rational konzipierter Mutantenbibliotheken erzielt und kann vermutlich mit einer größeren Anzahl von Substraten und NRPS‐Modulen repliziert werden. Die evolvierte NRPS ist in der Lage, ein Piz‐beinhaltendes Gramicidin S‐Analogon zu produzieren. Damit geben wir der zu früh verworfenen Idee neuen Auftrieb, dass weithin zugängliche Methoden mit niedrigem Durchsatz die Spezifität von NRPS in einer biosynthetisch nützlichen Weise verändern können.